Agenus Inc.
AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulā¦ read more
Healthcare
Biotechnology
23 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.53
Price0.00%
$0.00
1Y
Price
Market Cap
$144.344m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$99.524m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$190.646m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$8.77
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
-$322.398m
$200.201m
Assets$522.599m
Liabilities$92.043m
DebtDebt to Assets
46.0%
-1.1x
Debt to EBITDAFree Cash Flow
-$145.780m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company